Breaking News
A recent study shows the use of hormone therapy in postmenopausal women was associated with a significantly higher incidence and risk of autoimmune diseases.
The HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older who are prescribed HYQVIA.
Grifols Therapeutics has initiated a voluntary withdrawal of four lots of Gamunex-C 10%.
BioTrending
- By Keith Berman, MPH, MBA
Therapeutic plasma exchange may improve outcomes for patients diagnosed with sepsis or septic shock, but funding is needed to conduct needed clinical trials.
- By Trudie Mitschang
As chronic disease and aging populations drive healthcare costs higher, value-based care offers a sustainable path forward — rewarding providers for better outcomes, improved patient experiences and greater cost-efficiency.
- By Diane L.M. Cook
With a pending shortage of cardiologists, there is a growing need for remote cardiac monitoring, and now, three FDA-cleared products are transforming how this care is provided.
- By Lee Warren
The use of AI is growing at a brisk rate as healthcare professionals realize its potential as an indispensable partner in treating patients.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
